Form 4: BIOLIFE SOLUTIONS Executive Sells Shares Under Pre-Arranged Tax Plan

BIOLIFE SOLUTIONS' Chief Quality and Operations, Karen A. Foster, sold 251 shares of common stock for $22.46 per share to satisfy tax withholding obligations under a Rule 10b5-1 trading plan.

Summary

• Karen A. Foster, Chief Quality and Operations at BIOLIFE SOLUTIONS INC (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 251 shares of common stock.
• The shares were sold at a price of $22.46 per share.
• The sale occurred on May 28, 2025.
• Following this transaction, Karen A. Foster beneficially owns 195,316 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on February 24, 2022.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, pre-planned sale for tax withholding purposes, which is a common occurrence for executives receiving equity compensation and does not typically indicate a change in management's confidence or the company's operational performance.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to share disposition rather than a discretionary sale based on market timing.
• The sale was explicitly for tax withholding obligations, which is a common and routine reason for insider sales and does not necessarily reflect a negative outlook on the company's future.

Negatives

• An insider selling shares, even for tax purposes, can sometimes be perceived negatively by the market, though the stated reason mitigates this concern.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as it solely reports an individual insider transaction.

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of February 24, 2022, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's stock activity within the biotechnology or life sciences tools sector, where BIOLIFE SOLUTIONS operates.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by an executive for tax purposes is unlikely to have a significant direct impact on the company's share price or long-term shareholder value, especially given it was pre-planned.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

BIOLIFE SOLUTIONS, BLFS, Form 4, Insider Transaction, Stock Sale, Rule 10b5-1, Tax Withholding, Executive Compensation